



ophthalmology  
futures forums

Virtual2021

10

**YEAR  
ANNIVERSARY**  
OF OUR EUROPEAN FORUMS

**EUROPEAN FORUM**

*VIRTUAL*

Thur. 07 October



**European Programme**  
*Virtual 2021*



# Imagine Your Happiness

Vision, a window to the world.  
With vision, we connect with others.  
With vision, we feel happiness.

That is why we at Santen believe  
seeing is integral to life.  
As a company focused on vision,  
we explore and grow the unlimited potential  
of our ability to see.  
Because we know we can one day  
achieve a world free of vision problems.  
Because we know we can one day  
create a future full of smiles  
where everyone's vision is nurtured.  
Until then, we will not stop challenging ourselves.



Imagine Your Happiness

# CONTENTS:

## EUROPEAN PROGRAMME

<b>Welcome</b>	3
<b>Timings</b>	4
<b>Speakers</b>	
Presenting companies   Pannelists   Chairs	6
<b>Our sponsors</b>	7
Platinum	9
Gold	10
Silver	11
Bronze	12
New innovator	13
<b>European Forums 2022</b>	14
<b>Programme committee</b>	15



# WELCOME: EUROPEAN VIRTUAL FORUM

Dear colleagues,

Welcome to the Ophthalmology Futures European Forum 2021. The virtual format for this year's forum has presented us with challenges and opportunities. While missing the chance to network with participants in person, we are able to reach a much larger audience and include speakers who would otherwise not have been able to attend. This is our 10<sup>th</sup> annual European Forum and we are delighted to see the continued growth of the meeting, particularly in terms of the number of individuals and companies who participate.

Ophthalmology Futures is dedicated to creating a novel program for each meeting.

This Forum will highlight developments in the treatment of cataract, corneal endothelial disease, myopia and glaucoma. We will hear from corporate leaders regarding their strategies to emerge stronger post pandemic as well as from investors regarding the future outlook of the ophthalmology sector.

Ophthalmology Futures Forums thanks our key advisors, corporate presenters and distinguished faculty for their invaluable support and assistance. We would also like to especially thank our sponsors who have provided support allowing us to have this meeting without a registration fee for all attendees!

Thank you for joining us!

The Ophthalmology Futures Team



Vision Futures Limited, London, UK.  
Registered in England No: 8125858.





# TIMINGS:

## EUROPEAN VIRTUAL FORUM

TIMINGS ARE IN CENTRAL EUROPEAN SUMMER TIME

12:30 - 12:40

WELCOME FROM THE CO-CHAIRS

- Keith Barton
- Kuldev Singh

12:40 - 12:50

MARKET OVERVIEW

- Mike Giaquinto

12:50 - 13:20

PANEL 1: LOWER COST CAPSULOTOMY ALTERNATIVES TO FEMTO: ARE THEY MAKING AN IMPACT?

Co-chairs

- Soon-Phaik Chee
- Jorge Alio

Panel

- Vance Thompson
- Sunil Shah
- Richard Packard
- Erik Mertens
- Todd Pinkney

13:20 - 13:50

PANEL 2: THE FUTURE OF MYOPIA TREATMENT - OPTICAL OR PHARMA?

Chair

- Marcus Ang

Panel

- Reza Haque
- Olga Prenat
- Kelly Gottfried
- Stephen Newman
- Dirk Muehlhof

13:50 - 14:20

PANEL 3: SURGICAL AND PHARMACEUTICAL APPROACHES TO CORNEAL ENDOTHELIAL DISEASE

Co-chairs

- Kathryn Colby
- Jodbhir Singh Mehta

Panel

- Greg Kunst
- Robert Warner
- Gerd Auffarth
- Elizabeth Yeu
- Martin Dirisamer
- José Guell

14:20 - 15:20

COMPANY PRESENTATIONS I

- Aurion Biotech | Greg Kunst
- Eye-Yon Medical | Yishai Potack
- Recornea | Emiliano Lepore
- TECLens, LLC | Patrick Lopath
- CorNeat Vision Ltd | Almog Aley-Raz
- Dopavision | Hamed Bahmani
- Plano | Mohamed Dirani

15:20 - 15:35

CORPORATE LEADER INTERVIEW 1: HOW WE WILL EMERGE STRONGER POST PANDEMIC

Shigeo Taniuchi CEO of Santen interviewed by Kuldev Singh

15:35 - 16:05

PANEL 4: INTRAVITREAL, INTRACAMERAL AND EXTRAOCULAR DRUG DELIVERY FOR ANTERIOR SEGMENT: WHICH APPROACH IS BEST?

Chair

- Jonathan Crowston

Panel

- Mike Robinson
- Mike Goldstein
- Parisa Zamiri
- Joseph Panarelli

16:05 - 17:10

COMPANY PRESENTATIONS 2

- Ocuphire Pharma | Mina Sooch
- Eximore Ltd | Eyal Sheetrit
- Mitotech S.A. | Natalia Perekhvatova
- Tarsier Pharma | Daphne Haim Langford
- Photon Therapeutics Ltd | Sunil Shah
- NovaSight | Ran Yam
- Medevis Consulting SAS | Kristine Morrill

17:10 - 17:40

PANEL 5: THE OPHTHALMIC SECTOR: DOES PAST RETURN ON INVESTMENT JUSTIFY FUTURE OPTIMISM?

Co-chairs

- Kuldev Singh
- Andy Corley

Panel

- Peter Sallstig
- Scott Meyer
- Jane Rady
- Bruce Robertson

17:40 - 18:20

PANEL 6: INTRAOCULAR VS BLEB-FORMING EXTRAOCULAR GLAUCOMA SURGERY: WHERE IS THE GREATER UNMET NEED AND OPPORTUNITY?

Co-chairs

- Keith Barton
- Donald Budenz

Panel

- Chelvin Sng
- Omar Sadruddin
- Cody McKenzie
- Brett Trauthen
- Patrick Smale
- Stefano Gandolfi
- Julian Garcia-Feijoo

18:20 - 19:25

COMPANY PRESENTATIONS 3

- Advanced Ophthalmic Innovations Pte Ltd | Cherry Khoo
- iSTAR Medical | Michel Vanbrabant
- Sanoculis | Nir Israeli
- Radiance Therapeutics | Laurence Marsteller
- EYE TECH CARE | Dietrich Wolf
- Rheon Medical | Nikos Stergiopoulos
- Belkin Vision | Daria Lemann Blumenthal
- Sight Sciences | Shawn O'Neil

19:25 - 19:40

CORPORATE LEADER INTERVIEW 2: HOW WE WILL EMERGE STRONGER POST-PANDEMIC

David Endicott CEO of Alcon interviewed by Kuldev Singh

19:40 - 20:10

PANEL 7: OPPORTUNITIES IN OPHTHALMOLOGY - INVESTORS' PERSPECTIVE

Chair

- Katya Smirnyagina

Panel

- Wende Hutton
- Bram Vanparys
- Rusty Kelley
- Sabine Dandiguan

20:10 - 20:25

CORPORATE LEADER INTERVIEW 3: HOW WE WILL EMERGE STRONGER POST-PANDEMIC

Ludwin Monz CEO of Carl Zeiss Meditec interviewed by Kuldev Singh

20:25 - 21:05

COMPANY PRESENTATIONS 4

- GLANCE | George Kong
- MONA.health | Olivier Menage
- AcuFocus, Inc. | Yari Mitchell
- LensGen | Sumit Garg

21:05 - 21:45

PANEL 8: WHICH IOL WOULD YOU WANT IN YOUR EYE IF YOU HAD CATARACT SURGERY TODAY?

Co-chairs

- David Chang
- Arthur Cummings

Panel

- Douglas Koch
- Samuel Masket
- Marie-Jose Tassignon
- David Spalton
- Richard Packard
- Steven Schallhorn

21:45 - 22:15

PANEL 9: I HAVE AN IDEA. IS THERE A BIG EYE COMPANY LEFT TO CALL?

Chair

- Einar Stefánsson

Panel

- Eugene de Juan
- Chuck Hess
- Ken Araki
- Andrew Stewart

22:15 - 22:20


SUMMARY & CONCLUDING REMARKS

Co-chairs

- Keith Barton
- Kuldev Singh



## VISUAL FREEDOM IN ONE EXCEPTIONAL LENS



**Visian Toric ICL** provides outstanding refractive outcomes in patients with myopia and astigmatism<sup>1</sup>.

**The Visian Toric ICL clinical trial reported<sup>1</sup>:**

- **98.4%** of patients would have the Visian Toric ICL procedure again
- Predictable outcomes realized across a broad range of treatment options
- **93.8%** of eyes maintained or gained 1 or more lines of BSCVA
- Rapid and stable achievement of outstanding MRSE and MRCyl
- In eyes with pre-op BSCVA 20/20 or better **100%** of eyes obtained **20/40** or better UCVA
- Over **94%** of eyes maintained rotational stability of **≤5°** at all post-op time points

1 STAAR Surgical Visian Toric Implantable Collamer Lens PMA Supplement P030016 Ophthalmic Devices Advisory Panel, March 14, 2014

# SPEAKERS: PRESENTING COMPANIES PANNELISTS & CHAIRS

## CHAIRS & PANELLISTS

### A

- **Andrew Stewart**  
Associate VP, Retina, Allergan
- **Andy Corley**  
Chief Executive Officer,  
Yelroc Consulting, Inc.
- **Arthur Cummings**  
Consultant Ophthalmologist,  
Wellington Eye Clinic

### B

- **Bram Vanparys**  
Partner, GIMV
- **Brett Trauthen**  
Chief Scientific Officer,  
Ivantis, Inc.
- **Bruce Robertson**  
Managing Director,  
H.I.G. Capital

### C

- **Chelvin Sng**  
Associate Professor Singapore  
National University Hospital
- **Chuck Hess**  
VP & General Manager,  
Bausch+Lomb
- **Cody McKenzie**  
Franchise Head, Glaukos  
Corporation

### D

- **David Chang**  
Physician, Altos Eye Physicians
- **David Endicott**  
Chief Executive Officer, Alcon
- **David Spalton**  
Consultant Ophthalmologist,  
Prof Spalton
- **Dirk Muehlhof**  
Carl Zeiss Meditec AG
- **Donald Budenz**  
Professor and Chair, Dept of  
Ophthalmology, University of  
North Carolina
- **Douglas Koch**  
MD, Professor, Baylor College  
of Medicine

### E

- **Einar Stefánsson**  
Professor, University of Iceland
- **Elizabeth Yeu**  
Ophthalmologist, Virginia Eye  
Consultants
- **Erik Mertens**  
Medical Director, Medipolis
- **Eugene de Juan**  
Managing Partner, ForSight  
Labs, LLC

### G

- **Gerd Auffarth**  
Medical Director, Ruprecht-  
Karls University of Heidelberg
- **Greg Kunst**  
Chief Executive Officer,  
Aurion Biotech

### J

- **Jane Rady**  
SVP Business Development &  
Strategy, Glaukos Corporation
- **Jodhbhir Singh Mehta**  
Professor, Singapore National  
Eye Centre
- **Jonathan Crowston**  
Professor of Ophthalmology,  
Duke-NUS Medical School
- **Jorge Alio**  
Professor and Chairman  
of Ophthalmology,  
Vissum Oftalmologia
- **José Guell**  
Director Del Departamento De  
Córnea Y Cirugía Refractiva,  
Instituto de Microcirugia  
Ocular
- **Joseph Panarelli**  
Ophthalmologist, NYU  
Langone Health
- **Julian Garcia-Feijoo**  
Professor of Ophthalmology  
and Chair, Hospital Clinico San  
Carlos, Madrid

### K

- **Kathryn Colby**  
Chair, NYU Langone Health
- **Katya Smirnyagina**  
Senior Partner Life Sciences  
Oxford Science Enterprises
- **Keith Barton**  
Consultant Ophthalmologist,  
Moorfields Eye Hospital,
- **Kelly Gottfried**  
Head of Global Franchise  
Development, Johnson &  
Johnson Vision
- **Ken Araki**  
Head of Global Business  
Development Department,  
Santen Pharmaceutical Co., Ltd
- **Kuldev Singh**  
Professor of Ophthalmology  
& Director, Glaucoma Service,  
Stanford University Medical  
Center

### L

- **Ludwin Monz**  
President and Chief Executive  
Officer, Carl Zeiss Meditec AG

### M

- **Marcus Ang**  
Senior Consultant  
Ophthalmologist, Singapore  
National Eye Centre
- **Marie-Jose Tassignon**  
Professor, University of  
Antwerp. Medical Director,  
Antwerp University Hospital,  
Belgium
- **Martin Dirisamer**  
Cornea Specialist, Ludwig  
Maximilian University
- **Michael Giaquinto**  
Senior Managing Director,  
SVB Leerink
- **Michael Goldstein**  
President, Ophthalmology &  
Chief Medical Officer, Ocular  
Therapeutix
- **Michael Robinson**  
VP, Global Therapeutic Area  
Head Eye Care, Abbvie

### O

- **Olga Prenat**  
Vice President, Global  
Education and Professional  
Relations, Essilor International
- **Omar Sadruddin**  
Senior Medical Director,  
Santen Inc

### P

- **Parisa Zamiri**  
Chief Medical Officer,  
Graybug Vision
- **Patrick Smale**  
VP, Marketing, Surgical,  
Sight Sciences, Inc
- **Peter Sallstig**  
Global Head and Senior  
Vice President, Santen  
Pharmaceutical Co., Ltd

### R

- **Reza Haque**  
SVP and Global Head of OIC,  
Ophthalmic Innovation Center,  
Santen Inc
- **Richard Packard**  
Consultant, Arnott Eye  
Associates
- **Robert Warner**  
Chairman, EyeYon Medical
- **Rusty Kelley**  
Senior Vice President,  
Investments and Alliances,  
Foundation Fighting Blindness

### S

- **Sabine Dandiguan**  
Managing Partner, Jeito
- **Samuel Masket**  
Ophthalmologist, Clinical  
Professor - UCLA
- **Scott Meyer**  
Director, Carl Zeiss Meditec AG
- **Shigeo Taniuchi**  
President and CEO, Santen  
Pharmaceutical Co., Ltd
- **Soon-Phaik Chee**  
Senior Consultant, Singapore  
National Eye Centre
- **Stefano Gandolfi**  
Professor of Ophthalmology,  
University of Parma
- **Stephen Newman**  
Executive Officer, Global R&D  
& CTO, Menicon
- **Steven Schallhorn**  
Chief Medical Officer,  
Carl Zeiss Meditec, Inc.
- **Sunil Shah**  
Consultant ophthalmologist,  
Midland Eye

### T

- **Todd Pinkney**  
Chief Commercial Officer,  
Centricity Vision, Inc.

### V

- **Vance Thompson**  
Director of Refractive Surgery,  
Vance Thompson Vision

### W

- **Wende Hutton**  
General Partner,  
Canaan Partners

## PRESENTING COMPANIES

### A

- **AcuFocus, Inc.**  
Yari Mitchell, Chief Business  
Development Officer
- **Advanced Ophthalmic  
Innovations Pte Ltd**  
Cherry Khoo, Managing  
Director
- **Aurion Biotech**  
Greg Kunst, CEO

### B

- **Belkin Vision**  
Daria Lemann Blumenthal, CEO

### C

- **CorNeat Vision Ltd**  
Almog Aley-Raz, CEO &  
VP R&D

### D

- **Dopavision**  
Hamed Bahmani, Founder  
& CSO

### E

- **Eximore Ltd**  
Eyal Sheetrit, CEO
- **EYE TECH CARE**  
Dietrich Wolf, CEO
- **Eye-Yon Medical**  
Yishai Potack, VP Business  
Development

### G

- **GLANCE**  
George Kong, CEO

### I

- **iSTAR Medical**  
Michel Vanbrabant, CEO

### L

- **LensGen**  
Sumit Garg, Managing Director

### M

- **Medevis Consulting SAS**  
Kristine Morrill, GM & Founder
- **Mitotech S.A.**  
Natalia Perekhvatova, CEO
- **MONA.health**  
Olivier Menage, CEO

### N

- **NovaSight**  
Ran Yam, CEO

### O

- **Ocuphire Pharma**  
Mina Sooch, CEO

### P

- **Photon Therapeutics Ltd**  
Sunil Shah, Consultant  
Ophthalmologist
- **Plano**  
Mohamed Dirani,  
Managing Director

### R

- **Radiance Therapeutics**  
Laurence Marsteller, Founder  
& CEO
- **Recornea**  
Emiliano Lepore, CEO
- **Rheon Medical**  
Nikos Stergiopoulos, CEO

### S

- **Sanoculis**  
Nir Israeli, CEO
- **Sight Sciences**  
Shawn O'Neil, CCO

### T

- **Tarsier Pharma**  
Daphne Haim Langford, CEO
- **TECLens, LLC**  
Patrick Lopath, COO



ALL OF THE SPEAKERS FOR OUR EUROPEAN FORUM CAN BE FOUND  
ON OUR WEBSITE: [OPHTHALMOLOGY-FUTURES.COM/FORUMS](https://ophthalmology-futures.com/forums)



# SPONSORS: EURO FORUMS 2021

THANKS TO THE GENEROSITY OF OUR SPONSORS, THERE IS NO FEE FOR COMPANY PRESENTATIONS AND DELEGATE REGISTRATION IS COMPLIMENTARY FOR EVERYONE.

## PLATINUM



## GOLD



## SILVER



REGENXBIO



NOVARTIS

## BRONZE



IVERIC  
BIO



LENSAR

Ora



SIGHT  
SCIENCES

Apellis



## NEW INNOVATORS







# Stellest™ lenses:

Essilor's best solution  
to slow down myopia  
progression in  
children.

REGISTER NOW TO LEARN ABOUT THE  
FUTURE OF MYOPIA MANAGEMENT



# PLATINUM



Alcon is the global leader in eye care, dedicated to helping people see brilliantly. With our 70-plus-year heritage, we are the largest eye care device company in the world – with complementary businesses in Surgical and Vision Care. Being a truly global company, we work in over 70 countries and serve patients in more than 140 countries. We have a long history of industry firsts, and each year we commit a substantial amount in Research and Development to meet customer needs and patient demands.

For more information, please visit [www.alcon.com](http://www.alcon.com)



As a global specialized company dedicated exclusively to ophthalmology, Santen brings 130-year history of scientific knowledge and organizational capabilities to research, development, and commercialization of pharmaceutical, surgical, and OTC eye care products. Headquartered in Osaka, Japan, Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals. With more than 4,000 employees worldwide, Santen continues to grow its global presence across Asia, Europe, and North America, providing innovative solutions in retina, glaucoma, uveitis, dry eye, ocular allergy and infection to patients around the world.

For more information, please visit [www.santen.com](http://www.santen.com)



# GOLD



STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or "ICL", which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: [www.discovericl.com](http://www.discovericl.com). Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland.

For more information, please visit the Company's website at [www.staar.com](http://www.staar.com)

## Helping Doctors Improve Their Patients' Quality of Life.

ZEISS Medical Technology Business Group



### Improving Quality of Life

ZEISS Medical Technology is proud to support the **Ophthalmology Futures Retina Forum**

[www.zeiss.com](http://www.zeiss.com)



# SILVER



Essilor International is the world's leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, Eyezen™, Xperio®, Foster Grant®, and Bolon™. It also develops and markets equipment, instruments and services for eyecare professionals.

At Essilor we believe that people deserve the right vision solutions to unleash the full potential of their life, every day, all life long. That belief is anchored in the Group's mission. Essilor International is a subsidiary of EssilorLuxottica.

Please visit: [www.essilor.com](http://www.essilor.com)



REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy could potentially alter the course of disease significantly and deliver improved patient outcomes with long-lasting effects. We have developed a broad pipeline of gene therapy programs using our NAV® Technology Platform to address genetic diseases through two modalities: AAV-mediated antibody delivery and monogenic gene replacement. We believe this platform forms a strong foundation for our current programs and with our ongoing research and development, we expect to continue to expand the platform.

Please visit [www.regenxbio.com](http://www.regenxbio.com)



## Seeing beyond

The Medical Technology segment of ZEISS offers complete solutions to diagnose and treat ophthalmic diseases. With a special focus on ophthalmology and ophthalmic surgery, the company supports healthcare professionals in setting new standards of care with proven medical technology and broad application competence based on cutting-edge innovations.

For more information, please visit [www.zeiss.com/meditec/int/about-us.html](http://www.zeiss.com/meditec/int/about-us.html)



Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world.

Please visit: [www.novartis.com](http://www.novartis.com)



# BRONZE



GenSight Biologics is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases.

Developed as a treatment for Leber Hereditary Optic Neuropathy (LHON), GenSight Biologics' lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is currently in the review phase of its registration process in Europe, and in Phase III to move forward to a BLA filing in the U.S.

Our second lead product candidate, GS030, combines gene therapy with optogenetics and is currently in Phase I/II PIONEER to treat Retinitis Pigmentosa (RP).

For more information, please visit [www.gensight-biologics.com](http://www.gensight-biologics.com)



Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

For more information on the Company, please visit [www.ivericbio.com](http://www.ivericbio.com)



LENSAR  
CATARACT LASER WITH AUGMENTED REALITY

LENSAR®, Inc., the leader in next-generation femtosecond cataract laser technology, continues to focus on astigmatism with Streamline® IV. This includes enhancements unique to LENSAR that are dedicated to help surgeons confidently manage astigmatism and optimize patient outcomes, for both toric IOLs and arcuate incisions.

Enhancements include IntelliAxis Refractive Capsulorhexis®, which incorporates lenticular markings to guide precise and confident toric IOL alignment, and wireless transfer of preoperative data from multiple devices, for seamless treatment planning. Iris registration further contributes to accuracy by automatically accounting for cyclotorsion. The LENSAR Laser is revolutionizing the surgeon's ability to deliver great outcomes for astigmatic patients.

Please visit [www.lensar.com](http://www.lensar.com)



Ora is the world's leading full-service ophthalmic research organization with offices in the United States, United Kingdom, Australia, and Asia. For over 40 years, we have helped our clients earn 48 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's unique models, methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world's most extensive and experienced team of ophthalmic experts to maximize the value of new product initiatives.

For more information, please visit [www.oraclinical.com](http://www.oraclinical.com)



AcuFocus, Inc., is a privately held ophthalmic medical device company that delivers breakthrough small aperture intraocular products to address diverse unmet needs and help patients achieve their best personal vision. The IC-8 IOL is a first-of-its-kind presbyopia-correcting lens that delivers true extended depth of focus and enhanced adaptability through its distinctive, wavefront-filtering, small aperture design. The IC-8 IOL received CE mark in 2015 and is available in select markets across Europe and Asia.

Visit [www.AcuFocus.com](http://www.AcuFocus.com) for more information.



Apellis is a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing medicines.

At Apellis, we are committed to developing transformative therapies for people living with Geographic Atrophy (GA) by regulating complement, a part of the body's immune system.

Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases such as GA, where there are currently no treatment options available.

Please visit: [www.apellis.eu](http://www.apellis.eu)



EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment initially targeting wet AMD, the leading cause of vision loss among people 50 years of age and older in the United States. EyePoint's product candidate pipeline also includes YUTIQ® 50, a potential twice-yearly treatment for non-infectious uveitis affecting the posterior segment of the eye, and separately, two commercial products, YUTIQ and DEXYCU.

Please visit: [www.eyepointpharma.com](http://www.eyepointpharma.com)



Sight Sciences is a growth-stage medical device company dedicated to the development of intelligently designed and engineered products that address the underlying physiology of ophthalmic diseases. The company's portfolio consists of the OMNI® Surgical System which is a novel, implant-free device that can be used in combination with cataract surgery or as a standalone procedure, as well as the non-surgical TearCare® System which is a device that applies heat to the eyelids to remove blockage, the hallmark of MGD.

Please visit: [www.sightsciences.com](http://www.sightsciences.com)

# NEW INNOVATORS



LensGen®, a clinical stage ophthalmic medical device company headquartered in Irvine, California has developed a disruptive fluid-optic intraocular lens (IOL) for treating cataracts and presbyopia. With its innovative Juvene® IOL the company aims to bring to market this revolutionary device designed to restore full range of vision with quality optics and improved safety due to the modular, capsule filling design. The company is currently progressing through the IDE approval process and is planning a large Series B Financing in early 2021 that will fund the company through approval of the Juvene IOL pivotal FDA study.

For more information about the financing please contact Ramgopal Rao, CEO at [rrao@lensgen.com](mailto:rrao@lensgen.com) and visit [www.lensgen.com](http://www.lensgen.com)



Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company's proprietary ocular delivery technologies are designed to maintain effective drug levels in ocular tissue for six months and potentially longer, improving disease management, reducing healthcare burdens and ultimately delivering better clinical outcomes. Graybug's lead product candidate, GB-102, a microparticle depot formulation of the pan-vascular endothelial growth factor (VEGF) inhibitor, sunitinib malate, targeting a six-month or longer dosing regimen, inhibits multiple neovascular pathways for the intravitreal treatment of retinal diseases, including wet age-related macular degeneration. Graybug is also using its proprietary technologies to develop GB-401, an injectable depot formulation of a beta-adrenergic blocker prodrug, for primary open-angle glaucoma, with a dosing regimen of once every six months or longer, and GB-103, a longer-acting version of GB-102, designed to maintain therapeutic drug levels in the retinal tissue for 12 months with a single injection. Founded in 2011 on the basis of technology licensed from the Johns Hopkins University School of Medicine, Graybug is headquartered in Redwood City, California.

For more information, please visit [www.graybug.vision](http://www.graybug.vision) or contact us at [info@graybug.vision](mailto:info@graybug.vision).



iSTAR Medical pioneers minimally invasive, ophthalmic implants for powerful, safe and enduring treatment of patients with glaucoma. MINiject is a supraciliary MIGS device made from STAR® material, which is soft and flexible, medical-grade silicone with a micro-porous, multi-channel geometry enabling bio-integration of surrounding tissues. Clinical trials show that IOP is reduced by >40% to a mean of 13.8mmHg at two years post-surgery.

The US Food and Drug Administration (FDA) has approved the start of a pivotal trial for MINiject.

Please visit: [www.istarmed.com](http://www.istarmed.com)



A new name in the ophthalmic industry, Medevis Consulting brings together an experienced team to provide regulatory, clinical, market assessment and medical communication services for companies looking to succeed in Europe.

With unparalleled insight, resources and a network built up over decades of experience, we work with clients to build long-term relationships that ensure your European business thrives. As a team of specialists, we stand for ophthalmology innovation in Europe.

Please visit: [www.medevis.com](http://www.medevis.com)

# SAVE THE DATES

## EURO FORUMS

**Retina: Hamburg**

Weds. 31 August

**European: Milan**

Thurs. 15 September

[ophthalmology-futures.com](https://ophthalmology-futures.com)



**SEEKING TO IMPROVE LIVES  
THROUGH THE CURATIVE  
POTENTIAL OF GENE THERAPY**

### OUR COMMITMENT

REGENXBIO is committed to developing gene therapies that improve treatment options for people with serious diseases. The personal stories of patients and families help guide our work. We earn their trust through our actions and our words.

➤ For the latest updates on our programs, visit [REGENXBIO.com](https://REGENXBIO.com)



# PROGRAMME COMMITTEE

**Ike Ahmed** | Division Head, Ophthalmology, Trilium Health Partners, Toronto, Canada. Assistant Professor, University of Toronto, Canada. Clinical Assistant Professor, University of Utah, USA.

**Jorge Alio** | Professor & Chairman of Ophthalmology, Miguel Hernandez University, Alicante, President, Visum Corporation, Spain.

**Gerd Auffarth** | Professor & Chairman, Dept. of Ophthalmology, University of Heidelberg. Director, David J. Apple International Laboratory for Ocular Pathology, International Vision Correction Research Centre, Heidelberg, Germany.

**Francesco Bandello** | Full Professor & Chairman Department of Ophthalmology, University Vita-Salute, Ospedale San Raffaele of Milan, Italy.

**David Chang** | Altos Eye Physicians & Clinical Professor, University of California, San Francisco, USA.

**Steve Charles** | Founder & CEO, Charles Retina Institute Clinical Professor of Ophthalmology, University of Tennessee, USA.

**Paul Chew** | Professor of Ophthalmology, National University of Singapore, Singapore.

**Beatrice Cochener** | Professor, Chairman, Ophthalmology Department, University Hospital, Brest, France. Past-president, European Society of Cataract & Refractive Surgeons.

**Jost Jonas** | Professor of Ophthalmology, Medical Faculty Mannheim, University of Heidelberg, Germany.

**Sir Peng Khaw** | Professor of Glaucoma & Ocular Healing, Director National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital & UCL Institute of Ophthalmology, London, UK.

**Shigeru Kinoshita** | Professor & Chair, Department of Ophthalmology, Kyoto Prefectural University of Medicine, Japan.

**Richard Lindstrom** | Founder & Attending Surgeon: Minnesota Eye Consultants, Minneapolis, USA. Adjunct Professor Emeritus: University of Minnesota, USA.

**Boris Malyugin** | Chief of Department of Cataract & Implant Surgery, Deputy Director General, S. Fyodorov Eye Microsurgery Complex State Institution, Moscow, Russia.

**Prof David Spalton** | Past-president, European Society of Cataract & Refractive Surgeons London, UK.

**Prof Dr Ingeborg Stalmans** | Head of the Glaucoma Clinic, University Hospitals UZ Leuven, Belgium. Head, Ophthalmology Research Group, University KU Leuven, Belgium.

**Paulo Eduardo Stanga** | London Vision Clinic Retina Lead Consultant Ophthalmologist & Vitreoretinal Surgeon. Professor of Ophthalmology & Retinal Regeneration, University of Manchester, UK.

**Paul Rosen** | Consultant Ophthalmic Surgeon, Oxford Eye Hospital, Oxford, UK.

**José-Alain Sahel** | Endowed Professor & Chairman, Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, USA. Professor of Ophthalmology, Sorbonne Université. Chairman Departments

of Ophthalmology, Quinze- Vingts National Ophthalmology Hospital & Rothschild Ophthalmology Foundation, Paris. Director, Institut de la Vision (Sorbonne Université, Inserm, CNRS, Paris).

**Chelvin Sng** | Associate Professor, Department of Ophthalmology, National University Hospital, Singapore.

**Julian D. Stevens** | Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, London, UK.

**Donald Tan Tiang Hwee** | Arthur Lim Professor, SNEC & Duke-NUS Medical School, Singapore. Partner & Senior Consultant Ophthalmic Surgeon, Eye & Retina Surgeons (ERS), Camden Medical Centre, Singapore.

**Marie-Jose Tassignon** | Past Chief & Chair Department of Ophthalmology Antwerp University & University Hospital Antwerp, Belgium.

**Adnan Tufail** | Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK. Professor, UCL Institute of Ophthalmology, London, UK.

**Tien Yin Wong** | Vice Dean, Academic & Clinical Development, Duke-NUS Medical School, Singapore. Provost's Chair Professor, National University of Singapore. Deputy Group CEO (Research & Education), SingHealth, Singapore. Medical Director & Senior Consultant Ophthalmologist, Singapore National Eye Centre. Chair, Ophthalmology & Visual Sciences Academic Clinical Programme. Chairman, Board of Directors, Singapore Eye Research Institute, Singapore.

## ADVISORS

**Laurent Attias** | Senior VP, Head of Strategy, BD&L & Market Access, Alcon, USA.

**Eugene de Juan** | Jean Kelly Stock Distinguished Chair, Ophthalmology, ForSight Labs & University of California, Menlo Park, California.

**Tom Dunlap** | Founder, Dunlap Ophthalmology Consulting, Board of Directors, Advisory Boards.

**Malvina Eydelman** | Director, Division of Ophthalmic & Ear, Nose & Throat Devices ODE/CDRH/FDA, USA.

**Akira Kurokawa** | Chairman. Santen Pharmaceutical Co.

**James Mazzo** | JGlobal President Ophthalmic Devices, Carl Zeiss Meditec, USA.

**Naveed Siddiqi** | Novo Ventures.

## ORGANISING COMMITTEE

**Keith Barton** | Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK, Professor of Ophthalmology, UCL, UK.

**Don Budenz** | Professor & Chairman, Department of Ophthalmology, University of North Carolina, USA.

**Lea Pietrolongo** | Operational Director, Ophthalmology Futures Forums, UK.

**Kuldev Singh** | Professor of Ophthalmology & Director, Glaucoma Service, Stanford University Medical Center, Palo Alto, USA.

**Chelvin Sng** | Associate Professor, Department of Ophthalmology, National University Hospital, Singapore.

**Sanny Yuzhen Jiang** | Honorary Clinical Fellow. Moorfields Eye Hospital. Senior Research Associate, University College London Institute of Ophthalmology, UK.







# We Help People See Brilliantly.

At Alcon, we aspire to lead the world in innovating life-changing vision products because when people see brilliantly, they live brilliantly.

Each year our products touch the lives of millions of people living with conditions like cataracts, retinal diseases, and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as a differentiated contact lens and lens care portfolio to help patients see, look and feel their best.

At Alcon, we are at the forefront of innovation, partnering with eye care professionals to bring the gift of sight to more people around the world. That's been our legacy for more than 70 years—and as the new Alcon, it's what guides our focus towards the brilliant future ahead.

Learn more at [alcon.com](https://alcon.com)

## CONNECT WITH US!



@AlconEyeCare  
@AlconCareers



@Alcon



@AlconLife

